 "tablets")
Strides Shasun rose as much as 7% to Rs 969 has after the company got USFDA approval for Ibuprofen Tablets.
“The US markets for Ibuprofen Tablets USP 200 gm (OTC) is approximately $520 million. The approval further strengthens company’s fast growing global OTC franchise. The product will be marketed by Strides Shasun in the US Markets under its OTC brand Nuprin,” the company said in a statement.
At 12:43 pm, the scrip was up 5% at Rs 950 as against the 0.2% fall in S&P BSE Sensex.
On the BSE, 80,000 shares were traded in the counter
“The US markets for Ibuprofen Tablets USP 200 gm (OTC) is approximately $520 million. The approval further strengthens company’s fast growing global OTC franchise. The product will be marketed by Strides Shasun in the US Markets under its OTC brand Nuprin,” the company said in a statement.
At 12:43 pm, the scrip was up 5% at Rs 950 as against the 0.2% fall in S&P BSE Sensex.
On the BSE, 80,000 shares were traded in the counter
